secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001739104-25-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q4 adjusted EPS $0.14, revenue $1.02B; FY 2025 guidance reflects FX headwinds
--------------------------------------------------------------------------------

- Q4 2024 revenue $1,020M (-1% reported, +4% organic CC); adjusted EPS $0.14 (vs $0.08); adjusted EBITDA $177M (17.4% margin).
- FY 2024 revenue $4,439M (flat reported, +3% organic CC); adjusted EPS $0.91 (vs $0.89); innovation revenue $461M (beat target).
- FY 2025 guidance: revenue $4,445-4,510M; adjusted EPS $0.80-0.86; adjusted EBITDA $830-870M; mid-single-digit organic CC growth.
- 2025 innovation revenue target raised to $640-720M; net leverage 4.3x; expects FX headwind of $110M to revenue, $45M to EBITDA.
- Q1 2025 guidance: revenue $1,155-1,180M; adjusted EPS $0.29-0.34; adjusted EBITDA $240-260M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000173910425000011/0001739104-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000173910425000011/elan-20250225.htm
  HTML page:      https://secwatch.observer/filing/0001739104-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer